The “Fifteenth Five-Year Plan for the Development of the Pharmaceutical Industry” jointly issued by 10 departments including the Ministry of Industry and Information Technology proposes that by 2030, biomedical R&D and application will be at the forefront of the world, innovation-driven efficiency will be fully released, systematic breakthroughs will be achieved in key core technologies in key areas, and the biomedical industry will accelerate to become an emerging pillar industry in the country. Looking ahead to the second half of the year, Ping An Pharmaceutical Select Fund manager Zhou Sicong believes that innovative drugs are expected to become an important main line of growth. From a financial perspective, since this week, nearly 30 innovative drug concept stocks have received additional positions from financiers, with pharmaceutical companies such as Kangde, Gloria Wing, Chengdu Pioneer, and Medici ranking among the highest in net financing purchases. We Wu Biotech, Hualan Biotech, and Warner Pharmaceuticals all received institutional research during the month. Based on institutional forecasts, 15 of the concept stocks that have received ratings from 10 or more institutions are expected to continue to increase by more than 10% in 2026 and 2027, including shares such as Pharmaceuticals Kangde, Hengrui Pharmaceuticals, Gloria Ying, Kanglong Chemical, and Colon Pharmaceuticals.

The “Fifteenth Five-Year Plan for the Development of the Pharmaceutical Industry” jointly issued by 10 departments including the Ministry of Industry and Information Technology proposes that by 2030, biomedical R&D and application will be at the forefront of the world, innovation-driven efficiency will be fully released, systematic breakthroughs will be achieved in key core technologies in key areas, and the biomedical industry will accelerate to become an emerging pillar industry in the country. Looking ahead to the second half of the year, Ping An Pharmaceutical Select Fund manager Zhou Sicong believes that innovative drugs are expected to become an important main line of growth. From a financial perspective, since this week, nearly 30 innovative drug concept stocks have received additional positions from financiers, with pharmaceutical companies such as Kangde, Gloria Wing, Chengdu Pioneer, and Medici ranking among the highest in net financing purchases. We Wu Biotech, Hualan Biotech, and Warner Pharmaceuticals all received institutional research during the month. Based on institutional forecasts, 15 of the concept stocks that have received ratings from 10 or more institutions are expected to continue to increase by more than 10% in 2026 and 2027, including shares such as Pharmaceuticals Kangde, Hengrui Pharmaceuticals, Gloria Ying, Kanglong Chemical, and Colon Pharmaceuticals.